Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 9;42(12):2045-2063.e10.
doi: 10.1016/j.ccell.2024.11.005.

Chemotherapy induces myeloid-driven spatially confined T cell exhaustion in ovarian cancer

Affiliations
Free article

Chemotherapy induces myeloid-driven spatially confined T cell exhaustion in ovarian cancer

Inga-Maria Launonen et al. Cancer Cell. .
Free article

Abstract

Anti-tumor immunity is crucial for high-grade serous ovarian cancer (HGSC) prognosis, yet its adaptation upon standard chemotherapy remains poorly understood. Here, we conduct spatial and molecular characterization of 117 HGSC samples collected before and after chemotherapy. Our single-cell and spatial analyses reveal increasingly versatile immune cell states forming spatiotemporally dynamic microcommunities. We describe Myelonets, networks of interconnected myeloid cells that contribute to CD8+ T cell exhaustion post-chemotherapy and show that M1/M2 polarization at the tumor-stroma interface is associated with CD8+ T cell exhaustion and exclusion, correlating with poor chemoresponse. Single-cell and spatial transcriptomics reveal prominent myeloid-T cell interactions via NECTIN2-TIGIT induced by chemotherapy. Targeting these interactions using a functional patient-derived immuno-oncology platform demonstrates that high NECTIN2-TIGIT signaling in matched tumors predicts responses to immune checkpoint blockade. Our discovery of clinically relevant myeloid-driven spatial T cell exhaustion unlocks immunotherapeutic strategies to unleash CD8+ T cell-mediated anti-tumor immunity in HGSC.

Keywords: immuno-oncology; multiomics; ovarian cancer; spatial biology; tumor microenvironment.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests P.K.S. is a co-founder and member of the BOD of Glencoe Software, is a member of the SAB for RareCyte, Nanostring, Reverb Therapeutics and Montai Health, and consults for Merck; he holds equity in Glencoe and RareCyte.

Update of

MeSH terms